{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T01:43:21Z","timestamp":1791251001232,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.critrevonc.2011.03.002","type":"journal-article","created":{"date-parts":[[2011,4,20]],"date-time":"2011-04-20T23:49:13Z","timestamp":1303343353000},"page":"163-184","source":"Crossref","is-referenced-by-count":86,"title":["Eribulin\u2014A review of preclinical and clinical studies"],"prefix":"10.1016","volume":"81","author":[{"given":"Umang","family":"Swami","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imran","family":"Chaudhary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Ghalib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.critrevonc.2011.03.002_bib0005","doi-asserted-by":"crossref","first-page":"4796","DOI":"10.1021\/ja00302a042","article-title":"Norhalichondrin A: an antitumor polyether macrolide from a marine sponge","volume":"107","author":"Uemura","year":"1985","journal-title":"J Am Chem Soc"},{"issue":"5","key":"10.1016\/j.critrevonc.2011.03.002_bib0010","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1351\/pac198658050701","article-title":"Halichondrins\u2014antitumor polyether macrolides from a marine sponge","volume":"58","author":"Hirata","year":"1986","journal-title":"Pure Appl Chem"},{"issue":"11","key":"10.1016\/j.critrevonc.2011.03.002_bib0015","doi-asserted-by":"crossref","first-page":"3339","DOI":"10.1021\/jm00115a027","article-title":"Isolation and structure of the cell growth inhibitory constituents from the western Pacific marine sponge Axinella sp.","volume":"34","author":"Pettit","year":"1991","journal-title":"J Med Chem"},{"issue":"9","key":"10.1016\/j.critrevonc.2011.03.002_bib0020","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1021\/jo00061a030","article-title":"Isolation and structure of halistatin 1 from the eastern Indian Ocean marine sponge Phakellia carteri","volume":"58","author":"Pettit","year":"1993","journal-title":"J Org Chem"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0025","unstructured":"Gravelos DG, Lake R, Blunt JW, Munro MHG, Litaudon MSP. Halichondrins: cytotoxic polyether macrolides. European Patent Office, Munich, Switzerland: Publication number EP 0 572 109 A1; 1993."},{"issue":"1","key":"10.1016\/j.critrevonc.2011.03.002_bib0030","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0163-7258(92)90028-X","article-title":"Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B","volume":"55","author":"Hamel","year":"1992","journal-title":"Pharmacol Ther"},{"issue":"24","key":"10.1016\/j.critrevonc.2011.03.002_bib0035","doi-asserted-by":"crossref","first-page":"15882","DOI":"10.1016\/S0021-9258(18)98491-7","article-title":"Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data","volume":"266","author":"Bai","year":"1991","journal-title":"J Biol Chem"},{"issue":"3","key":"10.1016\/j.critrevonc.2011.03.002_bib0040","first-page":"1013","article-title":"In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2011.03.002_bib0045","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0006-2952(93)90079-C","article-title":"Interaction of halichondrin B and homohalichondrin B with bovine brain tubulin","volume":"45","author":"Luduena","year":"1993","journal-title":"Biochem Pharmacol"},{"issue":"12","key":"10.1016\/j.critrevonc.2011.03.002_bib0050","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1158\/1078-0432.CCR-08-2429","article-title":"A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies","volume":"15","author":"Goel","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2011.03.002_bib0055","first-page":"119","article-title":"Comparative antitumor activities of halichondrins and vinblastine against human tumor xenografts","volume":"1","author":"Fodstad","year":"1996","journal-title":"J Exp Ther Oncol"},{"issue":"8","key":"10.1016\/j.critrevonc.2011.03.002_bib0060","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1021\/ja00034a086","article-title":"Total synthesis of halichondrin B and norhalichondrin B","volume":"114","author":"Aicher","year":"1992","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0065","series-title":"Anticancer agents from natural products","article-title":"Discovery of E7389, a Fully Synthetic Macrocyclic Ketone Analog of Halichondrin B","author":"Yu","year":"2005"},{"issue":"9","key":"10.1016\/j.critrevonc.2011.03.002_bib0070","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1358\/dot.2010.46.9.1519020","article-title":"Eribulin mesilate, a halichondrin B analogue, in the treatment of breast cancer","volume":"46","author":"Mani","year":"2010","journal-title":"Drugs Today (Barc)"},{"issue":"7","key":"10.1016\/j.critrevonc.2011.03.002_bib0075","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Cancer Ther"},{"issue":"7","key":"10.1016\/j.critrevonc.2011.03.002_bib0080","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","article-title":"Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase","volume":"7","author":"Okouneva","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"10.1016\/j.critrevonc.2011.03.002_bib0085","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1124\/mol.106.026641","article-title":"Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin","volume":"70","author":"Dabydeen","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"16","key":"10.1016\/j.critrevonc.2011.03.002_bib0090","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","article-title":"Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389","volume":"64","author":"Kuznetsov","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0095","unstructured":"F.D.A. U. S. Food and Drug Administration. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/201532lbl.pdf. Retreived on 16.11.10."},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0100","unstructured":"U. S. National Institutes of Health http:\/\/clinicaltrials.gov\/ct2\/results?term=e7389. Retreived on 13.11.10."},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0105","unstructured":"National Cancer Institute Drug Dictionary \u2013 Definition of eribulin mesylate. http:\/\/www.cancer.gov\/drugdictionary\/?CdrID=257773. Retreived on 13.11.10."},{"issue":"8","key":"10.1016\/j.critrevonc.2011.03.002_bib0110","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1358\/dof.2007.032.08.1127245","article-title":"Eribulin mesilate","volume":"32","author":"Wang","year":"2007","journal-title":"Drugs Future"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0115","unstructured":"Product information, USA, Eisai Inc."},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0120","unstructured":"National Cancer Institute, Division of Cancer Treatment and Diagnosis \u2013 Featured Agents. http:\/\/dctd.cancer.gov\/FeaturedAgents\/pdfs\/E7389SolicitationMarch2005.pdf. Retreived on 13.11.10."},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0125","article-title":"E7389, a novel antimicrotubule agent with potent p53-independent induction of p27, Bcl2 phosphorylation and cytotoxicity in nonsmall cell lung cancer (NSCLC)","volume":"22","author":"Kimura","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0130","series-title":"17th AACR-NCI-EORTC Int Conf Mol Targets Cancer Ther","article-title":"Comparison of the relative efficacies and toxicities of halichondrin B analogues","author":"Alley","year":"2005"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0135","series-title":"27th Annu San Antonio Breast Cancer Symp","article-title":"Synergestic combinations of E7389 (halichondrin B analogue) with conventional agaents:In vitro median effect analysis in cell lines with potential clinical implications","author":"Budman","year":"2004"},{"issue":"10","key":"10.1016\/j.critrevonc.2011.03.002_bib0140","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1158\/1535-7163.MCT-09-0301","article-title":"Tubulin-based antimitotic mechanism of E7974, a novel analogue of the marine sponge natural product hemiasterlin","volume":"8","author":"Kuznetsov","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"2nd ed.","key":"10.1016\/j.critrevonc.2011.03.002_bib0145","article-title":"In vivo efficacy of E7389, a synthetic analogue of the marine sponge antitubulin agent halichondrin B, against human tumor xenografts under monotherapy and combination therapy conditions","volume":"44","author":"Towle","year":"2003","journal-title":"Proc Am Assoc Cancer Res (AACR)"},{"issue":"Suppl. 8","key":"10.1016\/j.critrevonc.2011.03.002_bib0150","first-page":"viii42","article-title":"Assessment of neuropathy-inducing effects of eribulin mesylate versus paclitaxel and ixabepilone in mice","volume":"21","author":"Wozniak","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0155","series-title":"Proc Am Assoc Cancer Res","article-title":"Interaction of [3H]halichondrin B with tubulin","author":"Bai","year":"2009"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0160","article-title":"E7389 and ER-076349, synthetic halichondrin B analogs, suppress centromere dynamics in concert with mitotic block","volume":"45","author":"Okouneva","year":"2001","journal-title":"Proc Am Assoc Cancer Res (AACR)"},{"issue":"2nd ed.","key":"10.1016\/j.critrevonc.2011.03.002_bib0165","article-title":"E7389, a synthetic analog of halichondrin B, suppresses microtubule dynamics in living MCF7 cells by a novel mechanism","volume":"44","author":"Kamath","year":"2003","journal-title":"Proc Am Assoc Cancer Res (AACR)"},{"issue":"6","key":"10.1016\/j.critrevonc.2011.03.002_bib0170","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1021\/bi901810u","article-title":"Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability","volume":"49","author":"Smith","year":"2010","journal-title":"Biochemistry"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0175","series-title":"99th AACR Annual Meeting","article-title":"Eribulin (E7389) binds to 13 saturable sites at microtubule ends to inhibit microtubule dynamics","author":"Smith","year":"2008"},{"issue":"33","key":"10.1016\/j.critrevonc.2011.03.002_bib0180","doi-asserted-by":"crossref","first-page":"7927","DOI":"10.1021\/bi900776u","article-title":"Macromolecular interaction of halichondrin B analogues eribulin (E7389) and ER-076349 with tubulin by analytical ultracentrifugation","volume":"48","author":"Alday","year":"2009","journal-title":"Biochemistry"},{"issue":"16S","key":"10.1016\/j.critrevonc.2011.03.002_bib0185","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1200\/jco.2005.23.16_suppl.2012","article-title":"Sensitivity to halichondrin analog E7389 and hemiasterlin analog E7974 correlates with \u00dfIII tubulin isotype expression in human breast cancer cell lines","volume":"23","author":"Agoulnik","year":"2005","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.critrevonc.2011.03.002_bib0190","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/sj.bjc.6605489","article-title":"Class III beta-tubulin expression and in vitro resistance to microtubule targeting agents","volume":"102","author":"Stengel","year":"2010","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2011.03.002_bib0195","first-page":"3003","article-title":"Vinorelbine induces beta3-tubulin gene expression through an AP-1 Site","volume":"29","author":"Saussede-Aim","year":"2009","journal-title":"Anticancer Res"},{"issue":"2","key":"10.1016\/j.critrevonc.2011.03.002_bib0200","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1470-2045(08)70029-9","article-title":"Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents?","volume":"9","author":"Seve","year":"2008","journal-title":"Lancet Oncol"},{"issue":"16S","key":"10.1016\/j.critrevonc.2011.03.002_bib0205","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1200\/jco.2005.23.16_suppl.3036","article-title":"A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: a California Cancer Consortium trial","volume":"23","author":"Synold","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0210","article-title":"Human pharmacokinetics of E7389 (Halichondrin B analog), a novel anti-microtubule agent undergoing phase I investigation in the California Cancer Consortium (CCC)","volume":"22","author":"Synold","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"12","key":"10.1016\/j.critrevonc.2011.03.002_bib0215","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1158\/1078-0432.CCR-09-0360","article-title":"Phase I study of eribulin mesylate administered once every 21days in patients with advanced solid tumors","volume":"15","author":"Tan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0220","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1359-6349(08)72380-2","article-title":"A phase I study of eribulin mesylate (E7389) in patients with refractory cancers","volume":"6","author":"Minami","year":"2008","journal-title":"Eur J Cancer Suppl"},{"issue":"15 Suppl.","key":"10.1016\/j.critrevonc.2011.03.002_bib0225","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1200\/jco.2010.28.15_suppl.2582","article-title":"Eribulin mesylate pharmacokinetics in patients with hepatic impairment","volume":"28","author":"Witteveen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0230","series-title":"Abstract presented at the EORTC-NCI-AACR Symposium","article-title":"Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole","author":"Devriese","year":"2010"},{"issue":"15 Suppl.","key":"10.1016\/j.critrevonc.2011.03.002_bib0235","article-title":"Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors","volume":"28","author":"Swami","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15S","key":"10.1016\/j.critrevonc.2011.03.002_bib0240","article-title":"Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC)","volume":"27","author":"Jansen","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0245","series-title":"Annual meeting of the American Association for Cancer Research, vol. 7","article-title":"Structure-activity relationships of synthetic halichondrin B analog E7389: in vitro susceptibility to PgP-mediated drug efflux","author":"Zheng","year":"2003"},{"issue":"27","key":"10.1016\/j.critrevonc.2011.03.002_bib0250","doi-asserted-by":"crossref","first-page":"17118","DOI":"10.1074\/jbc.272.27.17118","article-title":"Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization","volume":"272","author":"Giannakakou","year":"1997","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.critrevonc.2011.03.002_bib0255","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00280-008-0755-1","article-title":"Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4","volume":"62","author":"Zhang","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"issue":"15","key":"10.1016\/j.critrevonc.2011.03.002_bib0260","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1093\/jnci\/89.15.1138","article-title":"Accelerated titration designs for phase I clinical trials in oncology","volume":"89","author":"Simon","year":"1997","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2011.03.002_bib0265","first-page":"7s","article-title":"Phase I and pharmacokinetic (PK) study of eribulin (E7389) in patients (pts) with renal dysfunction (RD) and advanced urothelial cancer (UC): a California Cancer Consortium Trial","volume":"28","author":"Synold","year":"2010","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2011.03.002_bib0270","article-title":"Phase I study of E7389\/gemcitabine combination in patients with advanced solid tumors","volume":"27","author":"Goel","year":"2009","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.critrevonc.2011.03.002_bib0275","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","article-title":"Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.critrevonc.2011.03.002_bib0280","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.critrevonc.2011.03.002_bib0285","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/jco.2010.28.15_suppl.1081","article-title":"Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer","volume":"28","author":"Iwata","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0290","article-title":"The place for eribulin in the treatment of metastatic breast cancer","author":"Gradishar","year":"2010","journal-title":"Curr Oncol Rep"},{"issue":"18S","key":"10.1016\/j.critrevonc.2011.03.002_bib0295","doi-asserted-by":"crossref","first-page":"7546","DOI":"10.1200\/jco.2007.25.18_suppl.7546","article-title":"Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC)","volume":"25","author":"Spira","year":"2007","journal-title":"J Clin Oncol"},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2011.03.002_bib0300","first-page":"15s","volume":"27","author":"Gitlitz","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0305","series-title":"2009 ASCO Genitourinary Cancers Symposium","article-title":"Phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC) stratified by prior taxane therapy","author":"de Bono","year":"2009"},{"issue":"18S","key":"10.1016\/j.critrevonc.2011.03.002_bib0310","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1200\/jco.2007.25.18_suppl.5057","article-title":"The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus criteria for phase II clinical trials for castration-resistant prostate cancer","volume":"25","author":"Scher","year":"2007","journal-title":"J Clin Oncol"},{"issue":"15 Suppl.","key":"10.1016\/j.critrevonc.2011.03.002_bib0315","doi-asserted-by":"crossref","first-page":"4556","DOI":"10.1200\/jco.2010.28.15_suppl.4556","article-title":"ECOG 5805: a phase II study of eribulin mesylate (E7389) in patients (pts) with metastatic castration-resistant prostate cancer (CRPC)","volume":"28","author":"Stein","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0320","unstructured":"E7389 in Treating Patients With Recurrent Ovarian Epithelial PPC, or Fallopian Tube Cancer. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00334893."},{"issue":"Suppl.","key":"10.1016\/j.critrevonc.2011.03.002_bib0325","first-page":"15s","article-title":"Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant epithelial ovarian cancer (PR-EOC): a CTEP-sponsored phase II study. 2009 ASCO Annual Meeting","volume":"27","author":"Hensley","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15S","key":"10.1016\/j.critrevonc.2011.03.002_bib0330","doi-asserted-by":"crossref","first-page":"10031","DOI":"10.1200\/jco.2010.28.15_suppl.10031","article-title":"Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052)","volume":"28","author":"Schoffski","year":"2010","journal-title":"J Clin Oncol"},{"issue":"15S","key":"10.1016\/j.critrevonc.2011.03.002_bib0335","doi-asserted-by":"crossref","first-page":"e15634","DOI":"10.1200\/jco.2009.27.15_suppl.e15634","article-title":"A phase II study of Halichondrin B analog eribulin mesylate (E7389) as second-line therapy for patients with advanced pancreatic cancer","volume":"27","author":"Moore","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0340","unstructured":"E7389 in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction. http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00365157."},{"issue":"15 Suppl.","key":"10.1016\/j.critrevonc.2011.03.002_bib0345","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1200\/jco.2010.28.15_suppl.4539","article-title":"Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)\u2014Final report: A California Cancer Consortium-led NCI\/CTEP-sponsored trial","volume":"28","author":"Quinn","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0350","article-title":"Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618","author":"Arnold","year":"2009","journal-title":"Invest New Drugs"},{"issue":"2","key":"10.1016\/j.critrevonc.2011.03.002_bib0355","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3816\/CBC.2010.n.023","article-title":"Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer","volume":"10","author":"Twelves","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0360","series-title":"ASCO Meeting Abstracts","first-page":"CRA1004","article-title":"A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane","author":"Twelves","year":"2010"},{"issue":"Suppl. 8","key":"10.1016\/j.critrevonc.2011.03.002_bib0365","article-title":"Eribulin Mesylate (E7389) vs. Treatment of Physician's Choice (TPC) in Patients (Pts) with Metastatic Breast Cancer (MBC): Subgroup Analyses from the EMBRACE Study","volume":"21","author":"Twelves","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0370","series-title":"Proc Am Assoc Cancer Res","article-title":"Second generation eribulin analogs: efficacy against multi-drug resistant tumors and brain tumors","author":"Narayan","year":"2009"},{"issue":"2","key":"10.1016\/j.critrevonc.2011.03.002_bib0375","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10549-010-0901-4","article-title":"Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes","volume":"122","author":"Hortobagyi","year":"2010","journal-title":"Breast Cancer Res Treat"},{"issue":"33","key":"10.1016\/j.critrevonc.2011.03.002_bib0380","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.critrevonc.2011.03.002_bib0385","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","article-title":"Randomized Phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"28","author":"Sparano","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.critrevonc.2011.03.002_bib0390","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S1470-2045(07)70041-4","article-title":"Gemcitabine plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer previously treated with anthracyclines and taxanes: final results of the phase III Spanish Breast Cancer Research Group (GEICAM) trial","volume":"8","author":"Mart\u00edn","year":"2007","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.critrevonc.2011.03.002_bib0395","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1200\/JCO.1995.13.10.2567","article-title":"Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer","volume":"13","author":"Jones","year":"1995","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.critrevonc.2011.03.002_bib0400","doi-asserted-by":"crossref","first-page":"4963","DOI":"10.1200\/JCO.2005.05.0294","article-title":"Phase III trial comparing three doses of docetaxel for second-line treatment of advanced breast cancer","volume":"24","author":"Harvey","year":"2006","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.critrevonc.2011.03.002_bib0405","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2 \u2013 negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.critrevonc.2011.03.002_bib0410","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/annonc\/mdp397","article-title":"Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial","volume":"21","author":"Joensuu","year":"2010","journal-title":"Ann Oncol"},{"issue":"26","key":"10.1016\/j.critrevonc.2011.03.002_bib0415","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.critrevonc.2011.03.002_bib0420","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"Seidman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.critrevonc.2011.03.002_bib0425","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1200\/JCO.1999.17.8.2355","article-title":"Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer","volume":"17","author":"Bishop","year":"1999","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.critrevonc.2011.03.002_bib0430","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.critrevonc.2011.03.002_bib0435","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines In Oncology. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp. Retrieved on 18.02.11."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842811000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,21]],"date-time":"2021-11-21T23:38:13Z","timestamp":1637537893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842811000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":87,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S1040842811000692"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2011.03.002","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}